Answers are grounded in this paper and cite their sources.
T-prolymphocytic leukemia (T-PLL) is a very rare but aggressive T-cell neoplasm affecting mainly elderly patients [ 1 ]. Clinical presentation typically involves progressive lymphocytosis, hepatosplenomegaly, lymphadenopathy, and extramedullary symptoms, although up to 20% of patients might initially present with a stable disease course [ 2 ]. Consensus criteria for diagnosis and treatment have only recently been defined and clinical trials remain sparse. Consequently, treatment options for patients with T-PLL are limited and reported outcomes in small single institution studies remain poor with a median overall survival of 7.5 to 19 months [ 1 , 2 , 3 ]. Currently, the IgG1 monoclonal CD52 antibody alemtuzumab is recommended as first-line treatment, achieving high initial response rates in newly diagnosed patients [ 4 ]. Alternatively, the combination of Fludarabine, Mitoxantrone and Cyclophosphamide (FMC) has been used. Subsequent autologous or allogenic hematopoietic stem cell transplant (HCT) in complete remission (CR) should follow in fit patients and can induce long-term disease-free survival. However, due to the disease demographics, only 30–50% of patients are eligible for intensive HCT regimens [ 5 , 6 ]. In refractory cases, Pentostatin and Bendamustine have shown limited efficacy, whereas newer options such as Ruxolitinib are being explored with promising early results [ 3 , 4 , 7 ].
No takes yet. Share an insight, caveat, or question.
Wolgast et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: